Inventiva (IVA) Depreciation & Amortization (CF) (2022 - 2025)
Inventiva (IVA) recorded quarterly Depreciation & Amortization (CF) of -$19.0 million in Q2 2025, down 17.2% quarter-over-quarter from -$16.2 million in Q4 2024, and down 42.54% on a YoY basis from -$33.1 million in Q2 2024.
Inventiva (IVA) Depreciation & Amortization (CF) (2022 - 2025) Analysis & Trends
Inventiva's Depreciation & Amortization (CF) history runs 4 years deep, the most recent figure standing at -$19.0 million for Q2 2025.
- In Q2 2025, Depreciation & Amortization (CF) fell 42.54% year-over-year to -$19.0 million; the TTM figure through Jun 2025 stood at -$19.0 million (down 42.54% YoY), while the FY2024 annual figure was -$16.2 million, down 40.84% from the prior year.
- Depreciation & Amortization (CF) was -$19.0 million for Q2 2025 at Inventiva, down from -$16.2 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of -$8.7 million in Q4 2022 to a low of -$19.0 million in Q2 2025.
- Historically, Depreciation & Amortization (CF) has averaged -$13.2 million across 4 years, with a median of -$12.4 million in 2024.
- The sharpest annual moves came in 2024 and 2025: Depreciation & Amortization (CF) retreated 29.29% in 2024, then slumped 42.54% in 2025.
- A 4-year view of Depreciation & Amortization (CF) shows it stood at -$8.7 million in 2022, then sank by 32.07% to -$11.5 million in 2023, then sank by 40.84% to -$16.2 million in 2024, then dropped by 17.2% to -$19.0 million in 2025.
- The last three Depreciation & Amortization (CF) figures came in at -$19.0 million (Q2 2025), -$16.2 million (Q4 2024), and -$13.3 million (Q2 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 1,395.22 |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 429,663.65 |
| 10 | Inventiva | 8.64 Mn | -260.09 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -19.03 Mn |
| Jun 30, 2025 | -19.03 Mn |
| Dec 31, 2024 | -16.24 Mn |
| Dec 31, 2024 | -16.24 Mn |
| Jun 30, 2024 | -13.35 Mn |
| Jun 30, 2024 | -13.35 Mn |
| Dec 31, 2023 | -11.53 Mn |
| Dec 31, 2023 | -11.53 Mn |
| Jun 30, 2023 | -10.33 Mn |
| Jun 30, 2023 | -10.33 Mn |
| Dec 31, 2022 | -8.73 Mn |
| Dec 31, 2022 | -8.73 Mn |